The HR for PPAT was remarkably high in tissue-specific cohorts, such as those for lung, breast, brain, hematopoietic, neuroendocrine, liver, or pancreatic cancer, in both the random-effects model and the fixed-effects model (Fig. 6b and Supplementary Fig. 11b), whereas the expression of GLS1 was not significantly related to cancer prognosis in any cancer type with the exception of colorectal cancer. Here, PPAT is linked to pancreatic neoplasm.